CD36 and metabolic dysfunction-associated steatohepatitis: Moreover, NAFLD and NASH patients show CD36 [87,88] and NASH patients exhibit FATP2 and 5 [87] gene upregulation in the liver, suggesting that these transporters contribute to hepatic steatosis and progression of fibrosis.